Livoletide, an unacylated ghrelin analogue, showed initially a significant reduction in hyperphagia, waist circumference and fat mass in PWS subjects, without changes in ghrelin concentrations [27], but these effects were not sustained after three months of treatment [28]. This evidence concerns the gene GHRL and Prader-Willi syndrome.